Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Multiple drug-eluting coronary artery stent for percutaneous coronary artery intervention

A technology of implants and vessels, applied in the field of percutaneous coronary angioplasty to treat heart disease and other vascular diseases, multi-drug eluting tubular vascular implants, can solve insignificant BM stents, Issues such as poor clinical outcomes and low open rates

Inactive Publication Date: 2010-01-20
R·L·小比约克
View PDF19 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, none of these approaches significantly reduced thrombosis or restenosis over prolonged periods
[0010] [0010] Synthetic grafts are also seeded with endothelial cells, but the clinical outcome of seeding with endothelium is generally poor, that is, the rate of patency after surgery is low
Furthermore, although drug-eluting (DE) coronary stents have shown superior short- and medium-term results in reducing the rate of neovascularization compared with bare-metal (BM) stents, postoperative Long-term (≥2 years) restenosis rates of more than 5-15% at 3 years are still substantial and not significantly better than BM stents in certain patient populations

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Multiple drug-eluting coronary artery stent for percutaneous coronary artery intervention
  • Multiple drug-eluting coronary artery stent for percutaneous coronary artery intervention
  • Multiple drug-eluting coronary artery stent for percutaneous coronary artery intervention

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0144] Agents: paclitaxel, sirolimus, fibronectin, and anti-PDGF monoclonal antibody.

[0145] [0143] Delivery method:

[0146] 1. Experimental stent delivery method - delivery from polymer matrix:

[0147] [0145] Agent solutions for the different layers prepared in a solvent miscible with the polymer carrier solution were mixed with the polymer solution at final concentrations ranging from 0.001 wt% to 30 wt% paclitaxel and sirolimus. Polymers that are biocompatible (i.e., do not elicit any adverse tissue reactions or promote mural thrombus formation) and degradable, such as lactone-based polyesters or copolyesters, e.g., polylactide, polycaprolactone - Glycolides, polyorthoesters; polyanhydrides; polyamino acids; polysaccharides; polyphosphazenes; poly(ether-ester) copolymers such as PEO-PLLA, or blends thereof. Nonabsorbable biocompatible polymers are also suitable candidates. Polymers such as polydimethylsiloxane; poly(ethylene-vinyl acetate); acrylate-based polymers or...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a combination of agents, including an anti-proliferative agent, an anti-inflammatory agent, an anti-growth factor, and an extracellular matrix (ECM) molecule coated on a stent to prevent acute and subacute thrombosis, enhance endothelial in-growth, and prevent neointimal hyperplasia, and / or suppress neovascularization, and thereby reduce restenosis rates for drug eluting stents. The present invention also relates to methods of using such multiple drug eluting stents for the treatment of heart disease and other vascular conditions.

Description

technical field [0001] [0001] The present invention relates generally to vascular implants, and more particularly to multiple drug-eluting tubular vascular implants and the use of such implants for A method of percutaneous transluminal coronary angioplasty to treat heart disease and other vascular conditions. Background technique [0002] [0002] Percutaneous transluminal coronary angioplasty (PCTA) is a well-established procedure for treating blockages, injuries, stenosis, thrombus, etc., which may be present in body lumens such as coronary arteries and other vessels. [0003] [0003] One widely used form of percutaneous coronary angioplasty utilizes a dilated balloon catheter that is introduced and advanced through a lumen or body vessel until its distal end is at the desired location in the vasculature. Once in position across the diseased site, the expandable portion or balloon of the catheter is inflated to a predetermined size using fluid under relatively high pressure....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61F2/06A61F2/90
Inventor R·L·小比约克
Owner R·L·小比约克
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com